"Texas Oncology is an independent private practice with more than 500 physicians and 210 locations across the state. Meeting the oncology needs of Texans for more than 35 years, the practice includes Texas Center for Proton Therapy, Texas Breast Specialists, Texas Oncology Surgical Specialists, and Texas Center for Interventional Surgery. As a lead participant in US Oncology Research, Texas Oncology played a role in the development of more than 100 FDA-approved therapies."

During the past decade, Texas Oncology-McAllen conducted 38 clinical trials. In the 10-year time frame, 38 clinical trials started and 29 clinical trials were completed, i.e. on average, 76.3% percent of trials that started reached the finish line to date. In the past 5 years, 22 clinical trials started and 13 clinical trials were completed. i.e. 59.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Texas Oncology-McAllen" #1 sponsor was "US Oncology Research" with 10 trials, followed by "Novartis Pharmaceuticals" with 5 trials sponsored, "Hoffmann-La Roche" with 4 trials sponsored, "Eli Lilly and Company" with 3 trials sponsored and "Genentech, Inc." with 3 trials sponsored. Other sponsors include 42 different institutions and companies that sponsored additional 43 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Oncology-McAllen" #1 collaborator was "Bristol-Myers Squibb" with 4 trials as a collaborator, "National Cancer Institute (NCI)" with 4 trials as a collaborator, "Eli Lilly and Company" with 3 trials as a collaborator, "Sanofi" with 3 trials as a collaborator and "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 2 trials as a collaborator. Other collaborators include 18 different institutions and companies that were collaborators in the rest 23 trials.

According to Clinical.Site data, the most researched conditions in "Texas Oncology-McAllen" are "Breast Cancer" (15 trials), "Metastatic Breast Cancer" (8 trials), "Carcinoma, Non-Small-Cell Lung" (2 trials), "Chronic Lymphocytic Leukemia (CLL)" (2 trials) and "Fallopian Tube Cancer" (2 trials). Many other conditions were trialed in "Texas Oncology-McAllen" in a lesser frequency.

Most popular intervention types in "Texas Oncology-McAllen" are "Drug" (62 trials), "Other" (5 trials), "Biological" (1 trials), "Device" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "Cyclophosphamide" (7 trials), "Paclitaxel" (7 trials), "Doxorubicin" (4 trials) and "Rituximab" (4 trials). Other intervention names were less common.

The vast majority of trials in "Texas Oncology-McAllen" are 49 trials for "All" genders, 19 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "Texas Oncology-McAllen". undefined are not yet recruiting, 12 are recruiting, 19 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 33 completed trials in Texas Oncology-McAllen, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Texas Oncology-McAllen, 2 "Phase 1" clinical trials were conducted, 27 "Phase 2" clinical trials and 36 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".